Study finds high rates of antibiotic resistance in Pseudomonas aeruginosa isolates from clinical samples, suggesting urgent need for effective treatment options.
Key Points
Pseudomonas aeruginosa isolates showed an alarming multidrug resistance rate of 80.76% for ticarcillin, emphasizing treatment challenges.
Among 160 clinical samples, 26 (16.25%) were confirmed as Pseudomonas aeruginosa, highlighting its prevalence in hospital settings.
Susceptibility testing identified amikacin as the most effective antibiotic, indicating potential for targeted treatment amid rising resistance.
The emergence of multidrug-resistant strains calls for ongoing surveillance and effective antibiotic stewardship to combat infections.